Let us help you take care of it now
ATTAIN-2 (NCT05872620) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes
While higher doses (particularly 54 mg) showed some increase in gastrointestinal-related events, these remained mild to moderate in severity and did not result in treatment discontinuation
While most people tolerate the medication well, some may experience temporary mild side effects that typically resolve within the first few weeks of treatment
Works with Diet & Exercise Best results are seen when combined with a healthy lifestyle
Studies on transected rat Achilles tendon show that BPC-157 treatment accelerates healing by promoting tendon fibroblast outgrowth from tendon explants and markedly increasing the migration potential of cultured tendon fibroblasts